Haematologica (Aug 2019)
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
- Carmen Fava,
- Giovanna Rege-Cambrin,
- Irene Dogliotti,
- Marco Cerrano,
- Paola Berchialla,
- Matteo Dragani,
- Gianantonio Rosti,
- Fausto Castagnetti,
- Gabriele Gugliotta,
- Bruno Martino,
- Carlo Gambacorti-Passerini,
- Elisabetta Abruzzese,
- Chiara Elena,
- Patrizia Pregno,
- Antonella Gozzini,
- Isabella Capodanno,
- Micaela Bergamaschi,
- Monica Crugnola,
- Monica Bocchia,
- Sara Galimberti,
- Davide Rapezzi,
- Alessandra Iurlo,
- Daniele Cattaneo,
- Roberto Latagliata,
- Massimo Breccia,
- Michele Cedrone,
- Marco Santoro,
- Mario Annunziata,
- Luciano Levato,
- Fabio Stagno,
- Francesco Cavazzini,
- Nicola Sgherza,
- Valentina Giai,
- Luigia Luciano,
- Sabina Russo,
- Pellegrino Musto,
- Giovanni Caocci,
- Federica Sorà,
- Francesco Iuliano,
- Francesca Lunghi,
- Giorgina Specchia,
- Fabrizio Pane,
- Dario Ferrero,
- Michele Baccarani,
- Giuseppe Saglio
Affiliations
- Carmen Fava
- Department of Clinical and Biological Sciences, University of Turin, Orbassano
- Giovanna Rege-Cambrin
- Department of Clinical and Biological Sciences, University of Turin, Orbassano
- Irene Dogliotti
- Department of Clinical and Biological Sciences, University of Turin, Orbassano
- Marco Cerrano
- Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin
- Paola Berchialla
- Department of Clinical and Biological Sciences, University of Turin, Orbassano
- Matteo Dragani
- Department of Clinical and Biological Sciences, University of Turin, Orbassano
- Gianantonio Rosti
- Institute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna
- Fausto Castagnetti
- Institute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna
- Gabriele Gugliotta
- Institute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna
- Bruno Martino
- Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria
- Carlo Gambacorti-Passerini
- University Milano Bicocca, San Gerardo Hospital, Monza
- Elisabetta Abruzzese
- Haematology Unit, S. Eugenio Hospital, Rome
- Chiara Elena
- Hematology Hunit, Fondazione IRCCS Policlinico San Matteo, Pavia
- Patrizia Pregno
- A.O. Città della Salute e della Scienza di Torino, Turin
- Antonella Gozzini
- SC Terapie Cellulari e Medicina Trasfusionale, AOU Careggi, Florence
- Isabella Capodanno
- Hematology, Azienda Unità Sanitaria Locale -IRCCS, Reggio Emilia
- Micaela Bergamaschi
- Division of Hematology 1, IRCCS AOU San Martino-IST, Genoa
- Monica Crugnola
- Division of Hematology, University Hospital of Parma, Parma
- Monica Bocchia
- Azienda Ospedaliera Universitaria, University of Siena, Siena
- Sara Galimberti
- Hematology Department, University of Pisa, Pisa
- Davide Rapezzi
- S.C. Ematologia, ASO S. Croce e Carle, Cuneo
- Alessandra Iurlo
- Haematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan
- Daniele Cattaneo
- Haematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan
- Roberto Latagliata
- Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome
- Massimo Breccia
- Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome
- Michele Cedrone
- UOC of Hematology, San Giovanni - Addolorata Hospital, Rome
- Marco Santoro
- Hematology Unit, University of Palermo, Palermo
- Mario Annunziata
- Division of Hematology, Ospedale Cardarelli, Naples
- Luciano Levato
- Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro
- Fabio Stagno
- Chair and Hematology Section, Ferrarotto Hospital, Catania
- Francesco Cavazzini
- Department of Medical Sciences -Haematology and Physiopathology of Haemostasis Section, Ferrara
- Nicola Sgherza
- Division of Hematology, IRCCS Ospedale Casa Sollievo Sofferenza, San Giovanni Rotondo
- Valentina Giai
- Division of Haematology, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria
- Luigia Luciano
- Division of Hematology - Departments of Clinical Medicine and Surgery, University of Naples Federico II, Naples
- Sabina Russo
- Department of Internal Medicine, AOU Policlinico di Messina, Messina
- Pellegrino Musto
- IRCCS, Centro Di Riferimento Oncologico Della Basilicata, Rionero in Vulture
- Giovanni Caocci
- Department of Medical Sciences, University of Cagliari, Cagliari
- Federica Sorà
- Hematology Department, University Cattolica del Sacro Cuore - Policlinico A. Gemelli, Rome
- Francesco Iuliano
- Presidio Ospedaliero N. Giannetasio - Azienda ASL 3, Rossano
- Francesca Lunghi
- Division of Haematology and Bone Marrow Transplant, Ospedale San Raffaele IRCCS, Milan
- Giorgina Specchia
- Division of Haematology with Transplant – Outpatients, Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari, Bari, Italy
- Fabrizio Pane
- Division of Hematology - Departments of Clinical Medicine and Surgery, University of Naples Federico II, Naples
- Dario Ferrero
- Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin
- Michele Baccarani
- Institute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna
- Giuseppe Saglio
- Department of Clinical and Biological Sciences, University of Turin, Orbassano
- DOI
- https://doi.org/10.3324/haematol.2018.205054
- Journal volume & issue
-
Vol. 104,
no. 8
Abstract
It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (P
